ArticleVeterinary medicine and science2025
Effect of Substituting Polyether Ionophore Anticoccidial Drugs With 1, 8-Cineole for the Control of Eimeria Infections in Broilers.
Article in Veterinary medicine and science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative evaluation of a novel phytochemical mixture and monensin on host- and pathogen-targeted strategies in broiler chickens challenged with Eimeria maxima.Poultry science · 2026Article
- UnderstandingFrontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCoccidiosis is an important parasitic disease of broiler chickens. Drug resistance to the polyether polyether Ionophore anticoccidial drugs (PACDs) caused by long-term use has emerged as a significant problem in commercial broiler chicken production.
objectivesThis study explored the feasibility of 1,8-cineole (CIN) in replacing PACD with broiler feeding experiments and intestinal microecological experiments.
methodsThis experiment selected 21-day-old Lingnan yellow (LNY) broilers and randomly divided them into 8 groups, with 30 chickens in each group. They were uniformly fed with full feed during the breeding period. The experimental groups were as follows: (i) three broiler groups that were fed a PACD supplementation (G1: Salinomycin Premix [SAP] 60 mg/kg; G2: Monensin Premix [MOP] 100 mg/kg and G3: Maduramicin Premix [MAP] 5 mg/kg), (ii) three broiler groups that were administered different CIN dosages (G4: CIN-L 100 mg/kg, G5: CIN-M 150 mg/kg and G6: CIN-H 250 mg/kg) and (iii) two control broiler groups (G7: infected control group and G8: healthy control group). On the 23rd day, all groups were infected with coccidian cysts, except the G8 group which was used as a blank control. After 2 weeks of continuous feeding, the growth performance changes of broilers were analysed, and the intestinal lesions of eight groups of broilers were analysed after slaughter.
resultsCompared with PACD treatment, the average daily feed intake (ADFI) of the three CIN-treated groups increased by 13%, whereas the feed conversion ratio (FCR) reduced by 28%. FCR value for the high-dose CIN treatment was 2.04, 34% decline which compared with control group infected with spore oocysts. The anticoccidial index (ACI) of all PACD treatments was less than 120, whereas the ACI of the middle- and high-dose CIN treatments was higher than 180. In comparison to the Eimeria-infected control group, the diversity and total number of the microbiota in the CIN treatments increased significantly. Moreover, CIN treatment favoured the proliferation of intestinal probiotics, especially Lactobacillus sp.
conclusionsCIN could have an inhibitory effect on parasite development as suggested in the gene function annotation of the intestinal microbiota. These results demonstrate that CIN may be a feasible natural alternative to anticoccidiosis drugs. So it was important to take precautions against and control coccidiosis in poultry production which has a lesser risk of creating resistance to substitutive PACDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.